cagrilintide clinical trial results weight loss News CagrisSema is a once-weekly injection
CagrisSema is a once weekly injection of semaglutide and cagrilintide. Phase 2 clinical trial results for CagriSema showed significant improvements in A1C, weight loss, and time in range, marking it as a promising Pharmacy Cagrilintide monotherapy led to ~11.8% weight loss vs 2.3% with placebo over 68 weeks in the phase 3 REDEFINE 1 trial for adults with obesity or overweight plus comorbidities. Read more CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 Hypertension The Obesity Wars of 2026 continue: Novo's Miss, Lilly's Supremacy, and the Quality of Weight Loss Pivot Subcutaneous Cagrilintide, Semaglutide Shows Significant Weight Loss in Type 2 Diabetes Trial Pharmacy Times Cagrilintide vs Retatrutide Compared Dosage Peptide
Pay in 4 interest-free payments of $5.97 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6



